1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Myocardial Ischemia in 13 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to determine whether a potent Rho-kinase inhibitor fasudil prevents the occurrence of myocardial ischemia in patients with microvascular angina attributable to coronary microvascular spasm." | 9.10 | Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. ( Hirakawa, Y; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2003) |
| ", M/F 26/10) who underwent intracoronary administration of fasudil during a procedure to resolve myocardial ischemia that was resistant to intracoronary nitrate administration." | 7.91 | Usefulness of intracoronary administration of fasudil, a selective Rho-kinase inhibitor, for PCI-related refractory myocardial ischemia. ( Hao, K; Ikeda, S; Kikuchi, Y; Matsumoto, Y; Miyata, S; Sakata, Y; Sato, K; Shimokawa, H; Shindo, T; Shiroto, T; Suda, A; Sugisawa, J; Takahashi, J; Tsuchiya, S, 2019) |
| " This study aimed to determine the protective effect of fasudil pretreatment combined with IPO on myocardial ischemia/reperfusion injury in rats and explore the possible mechanisms." | 7.80 | The protective effect of fasudil pretreatment combined with ischemia postconditioning on myocardial ischemia/reperfusion injury in rats. ( Guan, YE; Jia, DL; Li, WN; Shu, WQ; Wu, N, 2014) |
| "We sought to determine whether a potent Rho-kinase inhibitor fasudil prevents the occurrence of myocardial ischemia in patients with microvascular angina attributable to coronary microvascular spasm." | 5.10 | Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. ( Hirakawa, Y; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2003) |
| ", M/F 26/10) who underwent intracoronary administration of fasudil during a procedure to resolve myocardial ischemia that was resistant to intracoronary nitrate administration." | 3.91 | Usefulness of intracoronary administration of fasudil, a selective Rho-kinase inhibitor, for PCI-related refractory myocardial ischemia. ( Hao, K; Ikeda, S; Kikuchi, Y; Matsumoto, Y; Miyata, S; Sakata, Y; Sato, K; Shimokawa, H; Shindo, T; Shiroto, T; Suda, A; Sugisawa, J; Takahashi, J; Tsuchiya, S, 2019) |
| " This study aimed to determine the protective effect of fasudil pretreatment combined with IPO on myocardial ischemia/reperfusion injury in rats and explore the possible mechanisms." | 3.80 | The protective effect of fasudil pretreatment combined with ischemia postconditioning on myocardial ischemia/reperfusion injury in rats. ( Guan, YE; Jia, DL; Li, WN; Shu, WQ; Wu, N, 2014) |
| "Epicardial coronary stenosis causes myocardial ischemia; however, the role of coronary microvessels is poorly understood in the pathogenesis of effort angina." | 2.73 | Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. ( Fukumoto, Y; Hirakawa, Y; Hirooka, Y; Inokuchi, K; Ito, A; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2007) |
| "Adenosine acts as a cardioprotective agent by producing coronary vasodilation, decreasing heart rate and by antagonizing the cardiostimulatory effect of catecholamines; adenosine also exerts a direct negative inotropic effect." | 1.31 | Adenosine induced direct negative inotropic effect is abolished during global ischemia: role of protein kinase C and prostacyclin. ( Oriji, GK, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, Z | 1 |
| Qiu, B | 1 |
| Wang, Q | 1 |
| Wei, W | 1 |
| Huang, J | 1 |
| Duan, W | 1 |
| Miyahara, S | 1 |
| Jenke, A | 1 |
| Yazdanyar, M | 1 |
| Kistner, J | 1 |
| Immohr, MB | 1 |
| Sugimura, Y | 1 |
| Aubin, H | 1 |
| Kamiya, H | 1 |
| Okita, Y | 1 |
| Lichtenberg, A | 1 |
| Akhyari, P | 1 |
| Kikuchi, Y | 1 |
| Takahashi, J | 1 |
| Hao, K | 1 |
| Sato, K | 1 |
| Sugisawa, J | 1 |
| Tsuchiya, S | 1 |
| Suda, A | 1 |
| Shindo, T | 1 |
| Ikeda, S | 1 |
| Shiroto, T | 1 |
| Matsumoto, Y | 1 |
| Miyata, S | 1 |
| Sakata, Y | 1 |
| Shimokawa, H | 4 |
| Li, WN | 1 |
| Wu, N | 1 |
| Shu, WQ | 1 |
| Guan, YE | 1 |
| Jia, DL | 1 |
| Jawad, E | 1 |
| Arora, R | 1 |
| Mohri, M | 2 |
| Hirakawa, Y | 2 |
| Masumoto, A | 2 |
| Takeshita, A | 2 |
| Nishizawa, K | 1 |
| Wolkowicz, PE | 1 |
| Yamagishi, T | 1 |
| Guo, LL | 1 |
| Pike, MM | 1 |
| Vincelette, J | 1 |
| Pagila, R | 1 |
| Kawai, K | 1 |
| Ishii, M | 1 |
| Horimizu, Y | 1 |
| Vergona, R | 1 |
| Sullivan, ME | 1 |
| Morser, J | 1 |
| Dole, WP | 1 |
| Wang, YX | 1 |
| Fukumoto, Y | 1 |
| Inokuchi, K | 1 |
| Ito, A | 1 |
| Hirooka, Y | 1 |
| Przyklenk, K | 1 |
| Sussman, MA | 1 |
| Simkhovich, BZ | 1 |
| Kloner, RA | 1 |
| Yamamoto, Y | 1 |
| Ikegaki, I | 2 |
| Sasaki, Y | 1 |
| Uchida, T | 1 |
| Oriji, GK | 1 |
| Utsunomiya, T | 1 |
| Satoh, S | 1 |
| Toshima, Y | 1 |
| Asano, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Myocardial Ischemia
| Article | Year |
|---|---|
Chronic stable angina pectoris.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetanilides; Angina Pectoris; Antihypertensive Agent | 2008 |
2 trials available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Myocardial Ischemia
| Article | Year |
|---|---|
Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Aged; Cardiovascular Agents; Coronary | 2003 |
Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angina Pectoris; Cardiac Pacing, Artificial; Co | 2007 |
10 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Myocardial Ischemia
| Article | Year |
|---|---|
Fasudil on Myocardial Injury in Rats with Myocardial Ischemia and Reperfusion through Rho-ROCK Signal Pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Coronary Artery Disease; Humans; Ischemia; M | 2022 |
The combination approach with Rhokinase inhibition and mechanical circulatory support in myocardial ischemia-reperfusion injury: Rho-kinase inhibition and ventricular unloading.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Coronary Artery Disease; Humans; Male; Myoca | 2022 |
Usefulness of intracoronary administration of fasudil, a selective Rho-kinase inhibitor, for PCI-related refractory myocardial ischemia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Female; Humans; Male; Middle Aged; Myocardial I | 2019 |
The protective effect of fasudil pretreatment combined with ischemia postconditioning on myocardial ischemia/reperfusion injury in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiotonic Agents; Combined Modality Therap | 2014 |
Fasudil prevents KATP channel-induced improvement in postischemic functional recovery.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Heart; In Vitro Techniques; Magnetic Resonan | 2005 |
Inhibition of rho-kinase by hydroxyfasudil prevents vasopressin-induced myocardial ischemia in Donryu rats by attenuating coronary vasoconstriction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arginine Vasopressin; Blood Pressure; Electr | 2005 |
Does ischemic preconditioning trigger translocation of protein kinase C in the canine model?
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Biological Transport; Coronary Circulation; | 1995 |
The protein kinase inhibitor fasudil protects against ischemic myocardial injury induced by endothelin-1 in the rabbit.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cell Movement; Diltiazem; Electrocardiograph | 2000 |
Adenosine induced direct negative inotropic effect is abolished during global ischemia: role of protein kinase C and prostacyclin.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adenosine; Animals; Depression, Chemical; Drug Intera | 2000 |
Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Anesthesia; Angina Pectoris; Animals; Cardiac Pacing, | 2001 |